
Monday, December 12, 2022 2:55:33 PM


Liked By
Spread the love. Be the first to like this post!
Recent TNXP News
- Current Report Filing (8-k) • Edgar (US Regulatory) • 06/07/2023 11:06:14 AM
- Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2023 American Transplant Congress • GlobeNewswire Inc. • 06/07/2023 11:00:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 06/05/2023 11:07:15 AM
- Tonix Pharmaceuticals Announces Presentation of Data Supporting Development of Racemic and Single (S)-Isomer Tianeptine, Plastogen Anti-Depressants, at the American Society of Clinical Psychopharmacology Meeting • GlobeNewswire Inc. • 06/05/2023 11:00:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 06/01/2023 11:02:36 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 05/31/2023 11:07:42 AM
- Tonix Pharmaceuticals Announces Presentations Involving TNX-1500 (anti-CD40L mAb) at the 2023 American Transplant Congress • GlobeNewswire Inc. • 05/31/2023 11:00:00 AM
- Tonix Pharmaceuticals Announces Presentation at the 2023 BIO International Convention • GlobeNewswire Inc. • 05/30/2023 11:00:00 AM
- Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 05/25/2023 08:05:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 05/25/2023 11:06:32 AM
- Tonix Pharmaceuticals Announces Poster Presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting • GlobeNewswire Inc. • 05/25/2023 11:00:00 AM
- Tonix Pharmaceuticals to Present at the June 1st Virtual Investor Summit • GlobeNewswire Inc. • 05/24/2023 11:00:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 05/23/2023 11:06:35 AM
- Tonix Pharmaceuticals Announces the Isolation and Characterization of the (S)-Isomer of Tianeptine, TNX-4300 (Estianeptine), Now Under Development for Psychiatric and Neurodegenerative Diseases • GlobeNewswire Inc. • 05/23/2023 11:00:00 AM
- Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin) • GlobeNewswire Inc. • 05/22/2023 11:00:00 AM
- Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference • GlobeNewswire Inc. • 05/18/2023 11:00:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 05/17/2023 11:06:55 AM
- Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression • GlobeNewswire Inc. • 05/17/2023 11:00:00 AM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 05/10/2023 09:14:41 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 05/10/2023 09:12:44 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 05/10/2023 09:10:39 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 05/10/2023 09:09:29 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 05/10/2023 09:01:59 PM
- Tonix Pharmaceuticals Announces 1-for-6.25 Reverse Stock Split • GlobeNewswire Inc. • 05/09/2023 05:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 05/08/2023 11:06:22 AM
FEATURED Mass Megawatts Targets Profitable Fiscal Quarter Ending October 31 and Introduces New Tech for Potential Project Paybacks of Less Than Three Years on June 29 • Jun 9, 2023 7:15 AM
Home Advantage: How Domestic REE Supply Is Supercharging North American Companies • UURAF • Jun 9, 2023 9:37 AM
Defiance Drills Widest Silver Intercept to Date in the Veta Grande • DNCVF • Jun 8, 2023 1:15 PM
Interactive Strength Inc. d/b/a FORME Reports First Quarter 2023 Results • TRNR • Jun 8, 2023 10:53 AM
Sadot LLC Achieves $9.9 Million Net Income Threshold, Triggers Nomination of Final Three Board Positions • GRIL • Jun 8, 2023 9:09 AM
MRES: Institute of Biomedical Research unveils artificial intelligence (AI) powered initiatives within its CBD product range, psilocybin research, and cardiometabolic health solutions • MRES • Jun 7, 2023 10:06 AM